Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings of $5.45 per share beating Walls Streets expectations.

ME Staff
-
0

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported Q2 2018 earnings this Morning, coming in at $5.45 per share, beating Wall Street’s estimates of $4.60 per Share. Revenue for the quarter came in at $1.61 billion beating analyst estimates of $1.56 billion

Recent Insider Trading for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

  • On 7/10/2018 P Roy Vagelos, Chairman, sold 74,670 with an average share price of $367.22 per share and the total transaction amounting to $27,420,317.40.
  • On 7/5/2018 Joseph L Goldstein, Director, sold 2,000 with an average share price of $360.00 per share and the total transaction amounting to $720,000.00.
  • On 6/21/2018 P Roy Vagelos, Chairman, sold 74,710 with an average share price of $327.87 per share and the total transaction amounting to $24,495,167.70.
  • On 6/8/2018 Sanofi, Major Shareholder, sold 121,601 with an average share price of $309.31 per share and the total transaction amounting to $37,612,405.31.
  • On 5/24/2018 Neil Stahl, EVP, sold 11,407 with an average share price of $295.09 per share and the total transaction amounting to $3,366,091.63.
  • On 5/9/2018 George L Sing, Director, sold 7,000 with an average share price of $285.29 per share and the total transaction amounting to $1,997,030.00.



    About Company
    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

    Recent Analyst Rating for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)



      Recent Trading for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
      Shares of Regeneron Pharmaceuticals Inc closed the previous trading session at 397.00 up +25.97 7.00% with 401.5 shares trading hands.